Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)

Current Cancer Drug Targets

Volumn 11, Issue 1, 2011, Pages 123-129

  Santini, D ^a   Schiavon, G ^a   Vincenzi, B ^a   Cass, C E ^b   Vasile, E ^c   Manazza, A D ^d   Catalano, V ^e   Baldi, G G ^c   Lai, R ^b   Rizzo, S ^f   Giacobino, A ^g   Chiusa, L ^d   Caraglia, M ^h   Russo, A ^f   Mackey, J ^b   Falcone, A ^c   Tonini, G ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e SAN SALVATORE HOSPITAL   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g MOLINETTE HOSPITAL   (Italy)

^h SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Biliary tract cancer; Gemcitabine; HENT1; Predictive factor

Indexed keywords

BIOLOGICAL MARKER; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; HUMANS; IMMUNOHISTOCHEMISTRY;

EID: 78951484730     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911793743600     Document Type: Article

References (20)

1. Scheithauer, W. Review of gemcitabine in biliary tract carcinoma. Semin. Oncol. 2002, 29(6 Suppl 20), 40-45.
2. Dingle, B.H.; Rumble, R.B.; Brouwers, M.C. The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can. J. Gastroenterol. 2005, 19(12), 711-716.
3. Pasetto, L.M.; D'Andrea, M.R.; Falci, C.; Monfardini, S. Gemcitabine in advanced biliary tract cancers. Crit. Rev. Oncol. Hematol. 2007, 61(3), 230-242.
4. Baldwin, S.A.; Mackey, J.R.; Cass, C.E.; Young, J.D. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol. Med. Today 1999, 5(5), 216-224.
5. Mackey, J.R.; Mani, R.S.; Selner, M.; Mowles, D.; Young, J.D.; Belt, J.A.; Crawford, C.R.; Cass, C.E. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998, 58(19), 4349-4357.
6. Chow, L.; Lai, R.; Dabbagh, L.; Belch, A.; Young, J.D.; Cass, C.E.; Mackey, J.R. Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry. Mod. Pathol. 2005, 18(4), 558-564.
7. Damaraju, V.L.; Elwi, A.N.; Hunter, C.; Carpenter, P.; Santos, C.; Barron, G.M.; Sun, X.; Baldwin, S.A.; Young, J.D.; Mackey, J.R.; Sawyer, M.B.; Cass, C.E. Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney. Am. J. Physiol. Renal. Physiol. 2007, 293(1), F200-211.
8. Mackey, J.R.; Jennings, L.L.; Clarke, M.L.; Santos, C.L.; Dabbagh, L.; Vsianska, M.; Koski, S.L.; Coupland, R.W.; Baldwin, S.A.; Young, J.D.; Cass, C.E. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin. Cancer Res. 2002, 8(1), 110-116.
9. Seve, P.; Mackey, J.R.; Isaac, S.; Trédan, O.; Souquet, P.J.; Pérol, M.; Cass, C.; Dumontet, C. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung. Cancer 2005, 49(3), 363-370.
10. Spratlin, J.; Sangha, R.; Glubrecht, D.; Dabbagh, L.; Young, J.D.; Dumontet C.; Cass, C.; Lai, R.; Mackey, J.R. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 2004, 10(20), 6956-6961.
11. Farrell, J.J.; Elsaleh, H.; Garcia, M.; Lai, R.; Ammar, A.; Regine, W.F.; Abrams, R.; Benson, A.B.; Macdonald, J.; Cass, C.E.; Dicker, A.P.; Mackey, J.R. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009, 136(1), 187-195.
12. Mori, R.; Ishikawa, T.; Ichikawa, Y.; Taniguchi, K.; Matsuyama, R.; Ueda, M.; Fujii, Y.; Endo, I.; Togo, S.; Danenberg, P.V.; Shimada, H. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol. Rep. 2007, 17(5), 1201-1205.
13. Santini, D.; Perrone, G.; Vincenzi B.; Lai, R.; Cass, C.; Alloni, R.; Rabitti, C.; Antinori, A.; Vecchio, F.; Morini, S.; Magistrelli, P.; Coppola, R.; Mackey, J.R.; Tonini, G. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann. Oncol. 2008, 19(4), 724-728.
14. Eckel, F.; Jelic, S. Biliary cancer: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann. Oncol. 2009, 20 (Suppl 4), 46-48.
15. Rosai, J. Rosai and Ackerman's surgical pathology, 9th ed; Mosby: Edinburgh, 2004, 2953-2954.
16. Hezel, A.F.; Zhu, A.X. Systemic therapy for biliary tract cancers. Oncologist 2008, 13(4), 415-423.
17. Eckel, F.; Schmid, R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br. J. Cancer 2007, 96(6), 896-902.
18. Marechal, R.; Mackey, J.R.; Lai, R.; Demetter, P.; Peeters, M.; Polus, M.; Cass, C.E.; Young, J.; Salmon, I.; Devière, J.; Van Laethem, J.L. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res. 2009, 15(8), 2913-2919.
19. Molina-Arcas, M.; Moreno-Bueno, G.; Cano-Soldado, P.; Hernández-Vargas, H.; Casado, F.J.; Palacios, J.; Pastor-Anglada, M. Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells. Biochem. Pharmacol. 2006, 72(12), 1646-1656.
20. Tonini, G.; Fratto, M.E.; Vincenzi, B.; Santini, D. Classification of biliary tract cancer (BTC): evaluation of all entities. Ann. Oncol. 2009, 20(6), 1148-1149.